Refine by
Human Clinical Trial Articles & Analysis: Older
97 news found
Together, SOPHiA GENETICS and Boundless Bio pioneered the ecDNA Solution (ECS) algorithm to detect the presence of ecDNA using routine clinical next-generation sequencing (NGS) data. ECS is the first ecDNA clinical trial assay and was designed by SOPHiA GENETICS in alignment with FDA guidelines as an Investigational Use Only ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart ...
Viral vectors can be used for the treatment of various diseases such as: muscular, metabolic, hematologic, ophthalmologic, and infectious diseases as well as different types of cancer. An increasing number of clinical trials in the field of viral vector therapy and viral vector manufacturing, confirms the value of this new medicinal technology, and ...
ByNuvonis
” The ‘776 patent further strengthens the company’s intellectual property position and coverage for their tau oligomer formation inhibitors and provides product protection for Oligomerix’s lead clinical candidate, OLX-07010, including composition of matter and methods of use until October 2037. ...
CTH-001 for the treatment of CTCL is the first product candidate progressing into human clinical trials. A second candidate, CTH-004, is being developed for the treatment of ovarian cancer. ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the ...
Professor Alan Trounson, CEO of Cartherics, said “We are excited to be working with a premier global cancer centre to advance CTH-001 into human clinical trials. We are very pleased to partner with Peter Mac’s Centre of Excellence in Cellular Immunotherapy, which was established in 2019 with backing from the Australian Federal ...
Immune-Onc also announced successful completion of dose escalation in the first-in-human clinical trial (NCT05054348) of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), for the treatment of solid tumors. ...
PT, in Carlsbad, CA Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Chief Medical Officer Maria Escolar, M.D, MS., will present updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the Company’s novel gene therapy for the treatment of patients ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. ...
The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany. RESKUE is the first-in-human clinical trial where subjects are administered FBX-101, an Adeno-Associated Virus (AAV) systemic gene replacement strategy, after full myeloablation and ...
The investment consists of an upfront investment of $25 million, $12.5 million now and $12.5 to be paid in six months, and two potential follow-on equity investments of $15 million each contingent upon (i) the commencement of the ENA-001 Phase 2 clinical trial, and (ii) the ENA-001 Phase 2 clinical trial reaching 50% enrollment. ...
Fain to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development leading to human clinical trials and commercialization of the company’s novel and proprietary heart pump. ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. ...
Food and Drug Administration (FDA) to launch the first-in-human clinical trial of ASC618. The study (NCT04676048) is expected to assess the one-time gene therapy’s safety and preliminary effectiveness in up to 12 adults with moderate to severe hemophilia A. ...
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at ...
He will also be working closely with Titan’s product development and the quality and regulatory affairs teams as the company completes its Investigational Device Exemption (IDE) application and, following IDE approval, proceed to human clinical trials. “Bill brings the necessary skills, experience and energy to our Chapel Hill ...
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the ...
Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. ...